<DOC>
	<DOCNO>NCT02675868</DOCNO>
	<brief_summary>Noradrenaline catecholamine cornerstone treatment improvement hemodynamic parameter septic shock . Catecholamines exert profound immunomodulatory effect . Noradrenaline vitro inhibits LPS-induced pro-inflammatory cytokine production , however , action immune function vivo assess . Furthermore , effect immune system viable vasopressor alternative treatment septic patient , namely phenylephrine vasopressin , need establish human vivo .</brief_summary>
	<brief_title>Effects Vasopressors Immune Response</brief_title>
	<detailed_description>Rationale : Septic shock major medical challenge associate high mortality rate increase incidence . It become clear majority septic patient succumb initial pro-inflammatory `` hit '' , later time-point pronounce immunosuppressive state , call 'immunoparalysis ' . Noradrenaline catecholamine cornerstone treatment improvement hemodynamic parameter septic shock . However , catecholamine exert profound immunomodulatory effect mainly study adrenaline . It profoundly inhibit LPS-induced production TNF-α , enhance production anti-inflammatory IL-10 vitro , well animal human model inflammation . Although vitro study show noradrenaline inhibits LPS-induced pro-inflammatory cytokine production potently adrenaline , effect noradrenaline immune system vivo yet study . Furthermore , effect immune system viable vasopressor alternative treatment septic patient , namely phenylephrine vasopressin , need establish human vivo . Objective : To investigate whether noradrenaline exerts immunomodulatory effect human vivo compare noradrenaline vasopressor ( phenylephrine vasopressin ) . Study design : A randomized double-blind placebo-controlled study healthy human volunteer experimental endotoxemia . Study population : 40 healthy male volunteer , age 18-35 yr . Intervention : 1 . The noradrenaline group ( n= 10 ) : subject receive intravenous infusion noradrenaline 0.05 μg/kg/min 5 hour , start 60 minute intravenous administration 2 ng/kg LPS . 2 . The phenylephrine group ( n=10 ) : subject receive intravenous infusion phenylephrine 0.5 μg/kg/min 5 hour , start 60 minute intravenous administration 2 ng/kg LPS . . 3 . The vasopressin group ( n = 10 ) : subject receive intravenous infusion vasopressin 0.04 IU/min 5 hour , start 60 minute intravenous administration 2 ng/kg LPS . 4 . The placebo group ( n = 10 ) : subject receive intravenous infusion NaCl 0.9 % 5 hour , start 60 minute intravenous administration 2 ng/kg LPS . Main parameters/endpoints : The difference LPS-induced TNF-α plasma concentration follow endotoxemia noradrenaline placebo group</detailed_description>
	<mesh_term>Endotoxemia</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<mesh_term>Vasoconstrictor Agents</mesh_term>
	<criteria>Written inform consent Age ≥18 ≤35 yr Male Healthy Use medication Smoking Previous spontaneous vagal collapse History atrial ventricular arrhythmia ( Family ) history myocardial infarction stroke age 65 year Cardiac conduction abnormality ECG consist 2nd degree atrioventricular block complex bundle branch block Hypertension ( define RR systolic &gt; 160 RR diastolic &gt; 90 ) Hypotension ( define RR systolic &lt; 100 RR diastolic &lt; 50 ) Renal impairment ( define plasma creatinin &gt; 120 μmol/l ) Liver enzyme abnormality Medical history disease associate immune deficiency CRP &gt; 20 mg/L , WBC &gt; 12x109/L , clinically significant acute illness , include infection , within 4 week endotoxin administration Participation drug trial donation blood 3 month prior LPS challenge Use recreational drug within 7 day prior experiment day Recent hospital admission surgery general anaesthesia ( &lt; 3 month ) Known anaphylaxis hypersensitivity study drug excipients Recent anaesthesia halogenated agent Known cardiovascular disease ( coronary artery disease ) Known chronic nephritis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>noradrenaline</keyword>
	<keyword>vasopressin</keyword>
	<keyword>phenylephrine</keyword>
	<keyword>endotoxemia</keyword>
	<keyword>Lipopolysaccharide</keyword>
	<keyword>vasopressor</keyword>
</DOC>